Trimeris and Array BioPharma have renewed the drug development agreement between the two terms that targets HIV.

Under the deal, Trimeris will screen small molecule compounds created by Array for possible use against HIV. The companies have worked together since August of 2001.

Details of the agreement were not disclosed.